DK3533787T3 - Pyridonforbindelse som C-MET-hæmmer - Google Patents
Pyridonforbindelse som C-MET-hæmmer Download PDFInfo
- Publication number
- DK3533787T3 DK3533787T3 DK17864813.5T DK17864813T DK3533787T3 DK 3533787 T3 DK3533787 T3 DK 3533787T3 DK 17864813 T DK17864813 T DK 17864813T DK 3533787 T3 DK3533787 T3 DK 3533787T3
- Authority
- DK
- Denmark
- Prior art keywords
- met inhibitor
- pyridone compound
- pyridone
- compound
- inhibitor
- Prior art date
Links
- -1 Pyridone compound Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610954377 | 2016-10-27 | ||
| PCT/CN2017/107964 WO2018077227A1 (zh) | 2016-10-27 | 2017-10-27 | 作为c-MET抑制剂的吡啶酮类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3533787T3 true DK3533787T3 (da) | 2020-11-30 |
Family
ID=62024383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17864813.5T DK3533787T3 (da) | 2016-10-27 | 2017-10-27 | Pyridonforbindelse som C-MET-hæmmer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10501443B2 (da) |
| EP (1) | EP3533787B1 (da) |
| JP (1) | JP6719679B2 (da) |
| KR (1) | KR102070748B1 (da) |
| CN (1) | CN109311812B (da) |
| AU (1) | AU2017348810B2 (da) |
| BR (1) | BR112019008415B1 (da) |
| CA (1) | CA3041164C (da) |
| CO (1) | CO2019005165A2 (da) |
| DK (1) | DK3533787T3 (da) |
| EA (1) | EA038108B1 (da) |
| ES (1) | ES2835301T3 (da) |
| HR (1) | HRP20201985T1 (da) |
| HU (1) | HUE051734T2 (da) |
| IL (1) | IL266126B (da) |
| LT (1) | LT3533787T (da) |
| MX (1) | MX374439B (da) |
| MY (1) | MY189557A (da) |
| PE (1) | PE20190912A1 (da) |
| PH (1) | PH12019500875B1 (da) |
| PL (1) | PL3533787T3 (da) |
| PT (1) | PT3533787T (da) |
| RS (1) | RS61126B1 (da) |
| SG (1) | SG11201903801YA (da) |
| SI (1) | SI3533787T1 (da) |
| UA (1) | UA122737C2 (da) |
| WO (1) | WO2018077227A1 (da) |
| ZA (1) | ZA201903074B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278281B2 (en) | 2018-04-26 | 2025-01-01 | Fujian Cosunter Pharmaceutical Co Ltd | Crystalline form of C–MET inhibitor and its salt form and method for preparing them |
| US11442063B2 (en) * | 2018-05-30 | 2022-09-13 | Promega Corporation | Broad spectrum kinase binding agents |
| WO2020156453A1 (zh) * | 2019-02-01 | 2020-08-06 | 南京明德新药研发有限公司 | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 |
| CN116171156B (zh) * | 2020-07-31 | 2025-07-04 | 江苏奥赛康药业有限公司 | 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法 |
| WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| CA3222061A1 (en) | 2021-06-04 | 2022-12-08 | Merck Patent Gmbh | Compounds for the treatment of glioblastoma |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ras相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586418B2 (en) * | 2000-06-29 | 2003-07-01 | Bristol-Myers Squibb Company | Thrombin or factor Xa inhibitors |
| JPWO2005085200A1 (ja) | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | ピリドン誘導体 |
| AU2008219166B2 (en) * | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| EP2768826A1 (de) | 2011-10-17 | 2014-08-27 | Bayer Intellectual Property GmbH | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| CA2867637A1 (en) * | 2012-03-19 | 2013-09-26 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| EP2906294B1 (en) * | 2012-10-11 | 2018-04-18 | Merck Patent GmbH | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
| AU2015360006B2 (en) * | 2014-12-11 | 2020-07-16 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
-
2017
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 EA EA201990952A patent/EA038108B1/ru unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/zh not_active Ceased
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/da active
- 2017-10-27 ES ES17864813T patent/ES2835301T3/es active Active
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/pt active IP Right Grant
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/en active Active
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/lt unknown
- 2017-10-27 CA CA3041164A patent/CA3041164C/en active Active
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/ko active Active
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 PH PH1/2019/500875A patent/PH12019500875B1/en unknown
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/ja active Active
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/es unknown
- 2017-10-27 MX MX2019004626A patent/MX374439B/es active IP Right Grant
- 2017-10-27 RS RS20201448A patent/RS61126B1/sr unknown
- 2017-10-27 PT PT178648135T patent/PT3533787T/pt unknown
- 2017-10-27 HR HRP20201985TT patent/HRP20201985T1/hr unknown
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 PL PL17864813T patent/PL3533787T3/pl unknown
- 2017-10-27 UA UAA201904417A patent/UA122737C2/uk unknown
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/hu unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/sl unknown
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/zh active Active
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286839A (en) | Propyne-indole compounds | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| DK3533787T3 (da) | Pyridonforbindelse som C-MET-hæmmer | |
| DK3472167T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| DK3377488T3 (da) | Heterocykliske forbindelser som immunomodulatorer | |
| DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
| DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
| DK3381918T3 (da) | 7-(Thiazol-5-yl)-pyrrolopyrimidinforbindelse som TLR7-agonist | |
| DK3390395T3 (da) | Forbindelser, der kan anvendes som kinase-inhibitorer | |
| DK3303348T3 (da) | Naphthyridinforbindelser som JAK-kinaseinhibitorer | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| DK3466949T3 (da) | Tricyklisk forbindelse som anticancermidler | |
| DK3519398T3 (da) | Pyridinforbindelse | |
| DK3533796T3 (da) | Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| DK3256462T3 (da) | Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel | |
| DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
| DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer | |
| DK3638680T3 (da) | Heteroaromatiske forbindelser som vanininhibitorer | |
| DK3458460T3 (da) | Imidazoler som histondemethylase-inhibitorer | |
| DK3562487T3 (da) | Metalloenzyminhibitorforbindelser |